

Exhibit B

Reference List

Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology* 2007 68: 515-521.

Aceto MD, Scates SM, Lowe JA, Martin BR. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. *Eur J Pharmacol* 1995;282(1-3): R1-2.

Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. *Addiction* 1996;91(11):1585-614.

Adler JN, Colbert JA. Clinical decisions, Medicinal use of marijuana--polling results, *N Engl J Med.* 2013 May 0;368(22):e30

Agrawal A; Pergadia ML; Lynskey MT: Is there evidence for symptoms of cannabis withdrawal in the National Epidemiologic Survey on Alcohol and Related Conditions? *Am J Addict* 2008; 17:199–208

Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. *Lancet.* 1987 Dec 26;2(8574):1483-6..

Arnold JC, Hone P, Holland ML, Allen JD. CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. *Pharmacol Rep.* 2012;64(3):751-7.

Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. *Br J Psychiatry.* 2004 Feb;184:110-7. Review.

Barnett G, Chiang CW, Perez-Reyes M, Owens SM. Kinetic study of smoking marijuana. *J Pharmacokinet Biopharm* 1982;10(5):495-506.

Baselt RC. *Drug effects on psychomotor performance.* Biomedical Publications, Foster City, CA; pp 403-415;2001.

Battistella G, Fornari E, Annoni JM, Chtioui H, Dao K, Fabritius M, Favrat B, Mall JF, Maeder P, Giroud C. Long-term effects of cannabis on brain structure. *Neuropsychopharmacology.* 2014 Aug;39(9):2041-8.

Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoids receptor-mediated inhibition of adenylyl cyclase. *J Biol Chem.* 1996 Apr 26;271(17):9902-5.

Bedi G, Foltin RW, Gunderson EW, Rabkin J, Hart CL, Comer SD, Vosburg SK, Haney M. Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. *Psychopharmacology (Berl).* 2010 Dec;212(4):675-86.

Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. *J Ethnopharmacol.* 2006 Apr 21;105(1-2):1-25.

Bicher HI, Mechoulam R. Pharmacological effects of two active constituents of marijuana. *Arch Int Pharmacodyn Ther.* 1968 Mar;172(1):24-31.

Böcker KB, Gerritsen J, Hunault CC, Kruidenier M, Mensinga TT, Kenemans JL. Cannabis with high δ 9-THC contents affects perception and visual selective attention acutely: an event-related potential study. *Pharmacol Biochem Behav.* 2010 Jul;96(1):67-74.

Bostwick JM, Reisfield GM, DuPont RL. *Clinical decision, Medicinal use of marijuana.* *N Engl J Med.* 2013 Feb 28;368(9):866-8

Brady JE and Li G, Trends in Alcohol and Other Drugs Detected in Fatally Injured Drivers in the United States, 1999-2010, *Am J Epidemiol.* 17: 692-699, 2014

Brady KT, Balster RL. The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys. *Psychopharmacology (Berl).* 1980;72(1):21-6.

Budney AJ; Hughes JR; Moore BA; Vandrey R: Review of the validity and significance of cannabis withdrawal syndrome. *Am J Psychiatry* 2004; 161:1967–1977.

Budney AJ; Moore BA; Vandrey RG; Hughes JR: The time course and significance of cannabis withdrawal. *J Abnorm Psychol* 2003; 112:393–402.

Budney AJ; Hughes JR: The cannabis withdrawal syndrome. *Curr Opin Psychiatry* 2006; 19:233–238

Budney AJ; Vandrey RG; Hughes JR; Moore BA; Bahrenburg B: Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. *Drug Alcohol Depend* 2007; 86:22–29

Budney AJ; Vandrey RG; Hughes JR; Thostenson JD; Bursac Z: Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. *J Subst Abuse Treat* 2008; 35:362–368

Buckner JD, Ecker AH, Cohen AS. Mental health problems and interest in marijuana treatment among marijuana-using college students. *Addict Behav.* 2010 Sep;35(9):826-33.

Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. *J Med Chem.* 1992 Aug 21;35(17):3135-41.

Caldeira KM, Kasperski SJ, Sharma E, Vincent KB, O'Grady KE, Wish ED, Arria AM. College students rarely seek help despite serious substance use problems. *J Subst Abuse Treat.* 2009 Dec;37(4):368-78.

Caldeira KM, Arria AM, O'Grady KE, Vincent KB, Wish ED. The occurrence of cannabis use disorders and other cannabis-related problems among first-year college students. *Addict Behav.* 2008 Mar;33(3):397-411.

Callaghan RC, Cunningham JK, Verdichevski M, Sykes J, Jaffer SR, Kish SJ. All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study. *Drug Alcohol Depend.* 2012 Oct1;125(3):290-4.

Calvigioni D, Hurd YL, Harkany T, Keimpema E. Neuronal substrates and functional consequences of prenatal cannabis exposure. *Eur Child Adolesc Psychiatry.* 2014 May 3.

Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. *J Clin Oncol.* 2006 Jul 20;24(21):3394-400.

Chadwick B, Miller ML, Hurd YL. Cannabis Use during Adolescent Development: Susceptibility to Psychiatric Illness. *Front Psychiatry.* 2013 Oct 14;4:129.

Cooper ZD, Haney M. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. *Psychopharmacology (Berl).* 2010 Aug;211(2):141-8.

Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. *Neuropsychopharmacology.* 2013 Sep;38(10):1984-92.

Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte T, Bentley H, Gouaux B. (2012). Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ,* 184 (10):1143-50.

Cornelius JR; Chung T; Martin C; Wood DS; Clark DB: Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. *Addict Behav* 2008; 33:1500–1505

Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. *Eur J Pharmacol.* 1982 Sep 24;83(3-4):293-8.

Chung T; Martin CS; Cornelius JR; Clark DB: Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. *Addiction* 2008; 103:787–

799

Copersino ML; Boyd SJ; Tashkin DP; Huestis MA; Heishman SJ; Derman JC; Simmons MS; Gorelick DA: Cannabis withdrawal among non-treatment-seeking adult cannabis users. *Am J Addict* 2006; 15:8–14

Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ. Effects of chronic, heavy cannabis use on executive functions. *J Addict Med.* 2011

Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. *J Addict Med.* 2011 Mar;5(1):1-8

Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, Flaxman AD, Engell RE, Freedman GD, Whiteford HA, Vos T. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. *PLoS One.* 2013 Oct 24;8(10):e76635.

Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. *Addiction.* 2013 Jan;108(1):124-33.

Degenhardt L, Hall WD. The adverse effects of cannabinoids: implications for use of medical marijuana. *CMAJ.* 2008 Jun 17;178(13):1685-6.

Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia.* 2014 Jun;55(6):791-802

D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. *Biol Psychiatry.* 2005 Mar 15;57(6):594-608

D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. *Neuropsychopharmacology.* 2004 Aug;29(8):1558-72.

D'Souza DC. Cannabinoids and psychosis. *Int Rev Neurobiol.* 2007;78:289-326.Review.

D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. *Neuropsychopharmacology.* 2008 Sep;33(10):2505-16

DuPont RL, Madras BK, Johansson P. Section 12: Policy Issues, Chapter 77, Drug policy: A biological science perspective. In J. H. Lowinson & P. Ruiz (Eds.) *Substance Abuse: A Comprehensive Textbook* (5th ed.). Lippincott Williams & Wilkins, 530 Walnut Street Philadelphia, PA 19106, 2011.

Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaughran F, David AS, Morgan C, Stahl D, Khondoker M, Maccabe JH, Murray RM. Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users. *Schizophr Bull.* 2014 Mar 19

Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, Beeri R, Pugatsch T, Tarsish E, Lotan C. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. *Am J Physiol Heart Circ Physiol.* 2007 Dec;293(6):H3602-7.

Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. (2009). Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial. *Neuropsychopharmacology*, 34(3), 672-80.

ElSohly, MA, NIDA Marijuana Project, Potency Monitoring Program Quarterly Report Number 119 Reporting Period: 09/16/2012 - 12/15/2012

FDA epilepsy trials: <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm401879.htm>

Fergusson DM, Boden JM. Cannabis use and later life outcomes. *Addiction.* 2008 Jun;103(6):969-76; discussion 977-8.

Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL. Cannabis use before age 15 and subsequent executive functioning. *Br J Psychiatry.* 2011 Jun;198(6):442-7.

Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant - do they exist? *Br J Pharmacol.* 2010 Jun;160(3):523-9.

Gilman JM, Kuster JK, Lee S, Lee MJ, Kim BW, Makris N, van der Kouwe A, Blood AJ, Breiter HC. Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. *J Neurosci.* 2014Apr 16;34(16):5529-38.

Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. *Drug Alcohol Rev.* 2003 Dec;22(4):453-60. Review.

Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. *Clin Pharmacol Ther.* 1994 Mar;55(3):324-8.

Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. *J Psychoactive Drugs*. 2014 Jan-Mar;46(1):73-7.

Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. *Drug Test Anal*. 2014 Jan-Feb;6(1-2):39-45.

Hall W, Degenhardt L. Cannabis and the increased incidence and persistence of psychosis. *BMJ*. 2011 Mar 1;342:d719.

Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet*. 2009 Oct 17;374(9698):1383-91.

Hanson KL, Winward JL, Schweinsburg AD, Medina KL, Brown SA, Tapert SF. Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. *Addict Behav*. 2010 Nov;35(11):970-6

Hansteen RW, Miller RD, Lonero L, Reid LD, Jones B. Effects of cannabis and alcohol on automobile driving and psychomotor tracking. *Ann NY Acad Sci* 1976;282:240-56.

Haney M; Hart CL; Vosburg SK; Nasser J; Bennett A; Zubarán C; Foltin RW: Marijuana withdrawal in humans: effects of oral THC or divalproex. *Neuropsychopharmacology* 2004; 29:158–170

Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. *J Acquir Immune Defic Syndr*. 2007 Aug 15;45(5):545-54.

Harley M, Kelleher I, Clarke M, Lynch F, Arseneault L, Connor D, Fitzpatrick C, Cannon M. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. *Psychol Med*. 2010 Oct;40(10):1627-34.

Hasin, DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. *Am J Psychiatry* 2013;170:834-851.

Hasin DS; Keyes KM; Alderson D; Wang S; Aharonovich E; Grant BF: Cannabis withdrawal in the United States: results from NESARC. *J Clin Psychiatry* 2008; 69:1354–1363

Heishman SJ. Effects of abused drugs on human performance: Laboratory assessment. In: *Drug Abuse Handbook*. Karch SB, ed. New York, NY: CRC Press, 1998, p219.

Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol Psychiatry*. 2012 Jun;17(6):642-9.

Hosking R, Zajicek J. Pharmacology: Cannabis in neurology-a potted review. *Nat Rev Neurol*. 2014 Jul 8.

Huestis MA. Cannabis (Marijuana) - Effects on Human Performance and Behavior. *Forens Sci Rev* 2002;14(1/2):15-60.

Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption phase of marijuana smoking. *Clin Pharmacol Ther* 1992;52(1):31-41.

Hurd YL, Michaelides M, Miller ML, Jutras-Aswad D. Trajectory of adolescent cannabis use on addiction vulnerability. *Neuropharmacology*. 2014 Jan;76 Pt B:416-24.

Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazarella E, Russo E Whalley BJ, Di Marzo V, Stephens GJ. The non-psychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. *ACS Chem Neurosci*. 2014 Jul 16. [Epub ahead of print]

The India Hemp Drugs Commission Report, 1894 (from other sources)

Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol Sci*. 2009 Oct;30(10):515-27

Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. *Curr Pharm Des*. 2014;20(13):2186-93.

Janefjord E, Mååg JL, Harvey BS, Smid SD. Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. *Cell Mol Neurobiol*. 2014 Jan;34(1):31-42.

Kalant H. Smoked marijuana as medicine: not much future. *Clin Pharmacol Ther*. 2008 Apr;83(4):517-9.

Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. *Prog Neuropsychopharmacol Biol Psychiatry*. 2004 Aug;28(5):849-63.

Kalant H Effects of Cannabis and Cannabinoids in the Human Nervous System, in *The Effects of Drug Abuse on the Human Nervous System*; B. Madras and M.J. Kuhar (Eds.), Elsevier, 2014

Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, Goodwin RS, Huestis MA. Subjective and physiological effects after controlled Sativex and oral THC administration. *Clin Pharmacol Ther*. 2011 Mar;89(3):400-7.

Katz NP, Birnbaum H, Brennan MJ, Freedman JD, Gilmore GP, Jay D, Kenna GA Madras BK, McElhaney L, Weiss RD, White AG. Prescription opioid abuse: challenges and opportunities for payers. *Am J Manag Care*. 2013 Apr;19(4):295-302.

Klonoff H. Marijuana and driving in real-life situations. *Science* 1974;186(4161):317-24.

Kogan NM, Schlesinger M, Priel E, Rabinowitz R, Berenshtein E, Chevion M, Mechoulam R. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. *Mol Cancer Ther*. 2007 Jan;6(1):173-83.

Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2014 Apr 29;82(17):1556-63.

Kouri EM; Pope HG Jr: Abstinence symptoms during withdrawal from chronic marijuana use. *Exp Clin Psychopharmacol* 2000; 8:483–492

Leirer VO, Yesavage JA, Morrow DG. Marijuana carry-over effects on aircraft pilot performance. *Aviat Space Environ Med* 1991;62(3):221-7.

Levin KH; Copersino ML; Heishman SJ; Liu F; Kelly DL; Boggs DL; Gorelick DA: Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. *Drug Alcohol Depend* 2010; 111:120–127

Lichtman AH; Martin BR: Marijuana withdrawal syndrome in the animal model. *J Clin Pharmacol* 2002; 42(suppl):20S–27S

Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. *ochrane Database Syst Rev*. 2013 Apr 30;4:CD005175.

Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *Br J Clin Pharmacol*. 2011 Nov;72(5):735-44

Maa E, Figi P. The case for medical marijuana in epilepsy. *Epilepsia*. 2014 Jun;55(6):783-6.

Madras BK, Miller G, Ogawa L, Zimmer J, Boisvert K, Vallendar E, Westmoreland S, Hurd Y. THC (Δ^9 -tetrahydrocannabinol) elicits persistent changes in expression of genes implicated in adolescent neurodevelopment, CPDD abstract, 2014.

Madras BK. Invited Commentary, Dopamine Challenge Reveals Neuroadaptive Changes in Marijuana Abusers. *Proc Natl Acad Sci, USA*, 2014, in press.

Madras BK. “Unique Consequences of Addiction” in the American Psychological Association Addiction Syndrome Handbook, HJ Shaffer, Ed., 2012.

Madras, B.K. Drug use and Consequences (2014) In: *The Effects of Drug Abuse on the Human Nervous System*; B. Madras and M.J. Kuhar (Eds.), Elsevier, in press.

Madras B.K. and Kuhar, MJ, (Eds.) *The Effects of Drug Abuse on the Human Nervous System*, Elsevier Press, 2014.

Madras BK. "Cell Biology of Addiction". Editors: Madras BK, Colvis CM, Pollack JD, Rutter JL, Shurtleff D, von Zastrow M, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 1-12, 2006. Madras BK and von Zastrow, M Preface to "Cell Biology of Addiction" Madras et al, Editors, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp ix-x, 2006.

Madras BK and Lin, Z. Cocaine Neurobiology: From targets to treatment approaches, in "Cell Biology of Addiction", Editors, Madras BK, Colvis CM, Pollack JD, Rutter JL, Shurtleff D, von Zastrow M, Editors, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 239-269, 2006.

Madras BK. Candidate performance measures for screening for, assessing, and treating unhealthy substance use in hospitals. *Ann Intern Med.* 2011 Jan 4;154(1):72-3;

Madras BK. Office of National Drug Control Policy: a scientist in drug policy in Washington, DC. *Ann N Y Acad Sci.* 2010 Feb;1187:370-402.

Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. *Drug Alcohol Depend.* 2009 Jan 1;99(1-3):280-95.

Mahmood OM, Jacobus J, Bava S, Scarlett A, Tapert SF. Learning and memory performances in adolescent users of alcohol and marijuana: interactive effects. *J Stud Alcohol Drugs.* 2010 Nov;71(6):885-94.

Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreaskos E, Mechoulam R, Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. *Proc Natl Acad Sci U S A.* 2000 Aug 15;97(17):9561-6.

Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Prognosis of schizophrenia in persons with and without a history of cannabis use. *Psychol Med.* 2014 Sep;44(12):2513-21.

Marijuana and Medicine: Assessing the Science Base, 2003, Janet E. Joy, Stanley J. Watson, Jr., and John A. Benson, Jr., Editors Division of Neuroscience and Behavioral Health, Institute of Medicine, National Academy Press Washington, D.C.

Marks MA, Chaturvedi AK, Kelsey K, Straif K, Berthiller J, Schwartz SM, Smith E, Wyss A, Brennan P, Olshan AF, Wei Q, Sturgis EM, Zhang ZF, Morgenstern H, Muscat J, Lazarus P, McClean M, Chen C, Vaughan TL, Wunsch-Filho V, Curado MP, Koifman S, Matos E, Menezes A, Daudt AW, Fernandez L, Posner M, Boffetta P, Lee YC, Hashibe M, D'Souza G. Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. *Cancer Epidemiol Biomarkers Prev.* 2014 Jan;23(1):160-71.

Martín-Sánchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. *Pain Med.* 2009 Nov;10(8):1353-68

Mason AP, McBay AJ. Cannabis: pharmacology and interpretation of effects. *J Forensic Sci* 1985;30(3):615-31.

Mechoulam R, Shani A, Edery H, Grunfeld Y. Chemical basis of hashish activity. *Science*. 1970 Aug 7;169(3945):611-2.

Mechoulam R, Parker L. Towards a better cannabis drug. *Br J Pharmacol*. 2013 Dec;170(7):1363-4.

Medina KL, Nagel BJ, Tapert SF. Abnormal cerebellar morphometry in abstinent adolescent marijuana users. *Psychiatry Res*. 2010 May 30;182(2):152-9.

Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci U S A*. 2012 Oct 2;109(40):E2657-64.

Meschler JP, Howlett AC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. *Psychopharmacology (Berl)*. 2001 Jun;156(1):79-85.

Meschler JP, Clarkson FA, Mathews PJ, Howlett AC, Madras BK. D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid-induced sedation in nonhuman primates. *J Pharmacol Exp Ther*. 2000 Mar;292(3):952-9.

Milin R; Manion I; Dare G; Walker S: Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study. *J Am Acad Child Adolesc Psychiatry* 2008; 47:174–178

Milazzo S, Ernst E, Lejeune S, Boehm K, Horneber M., *Laetrile treatment for cancer*, *Cochrane Database Syst Rev*. 2011 Nov 9;(11):CD005476

Moir et al, A Comparison of Mainstream and Sidestream Marijuana and Tobacco Cigarette Smoke Produced under Two Machine Smoking Conditions. *Chem. Res. Toxicol.*, 2008, 21 (2), pp 494–502

Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, Warrington P, Rupasinghe I, Ramoutar A, Tan N, Wingham G, Lewis S, Curran HV. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. *Psychol Med*. 2012 Feb;42(2):391-400.

Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. *Neuropsychopharmacology*. 2010 Aug;35(9):1879-85.

Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. *Br J Psychiatry*. 2010 Oct;197(4):285-90. Erratum in: *Br J Psychiatry*. 2010 Nov;197:416.

MTF (Monitoring the Future): Johnston, L. D., O'Malley, P. M., Bachman, J. G., & Schulenberg, J. E. (December 18, 2013). "American teens more cautious about using synthetic drugs." University of Michigan News Service: Ann Arbor, MI. Retrieved 07/25/2104 from <http://www.monitoringthefuture.org>

Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, Gao RY, Patel V, Wink DA, Liaudet L, Haskó G, Mechoulam R, Pacher P. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. *Free Radic Biol Med*. 2011 May 15;50(10):1368-81.

Murray RM, Morrison PD, Henquet C, Di Forti M, McGrath et al, Association Between Cannabis use and Psychosis-related outcomes using sibling pair analysis in a cohort of young adults. *Arch Gen Psychiatry* 2010; 67: 440-447

Neavyn MJ, Blohm E, Babu KM, Bird SB. Medical Marijuana and Driving: a Review. *J Med Toxicol*. 2014 Mar 20. [Epub ahead of print]

Niesink RJ, van Laar MW. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? *Front Psychiatry*. 2013 Oct 16;4:130

NSDUH (National Survey on Drug Use and Health): Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013

Palmer RS, McMahon TJ, Moreggi DI, Rounsaville BJ, Ball SA. College Student Drug Use: Patterns, Concerns, Consequences, and Interest in Intervention. *J Coll Stud Dev*. 2012 Jan;53(1).

Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. *Neuroreport*. 2002 Apr 16;13(5):567-70.

Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. *Pharmacol Rev*. 2010 Dec;62(4):588-631

Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. *PLoS One*. 2010 Dec 28;5(12):e14433.

Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with Dronabinol. *Pharmacol Biochem Behav* 1991;40(3):695-700.

Pope HG Jr, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. *JAMA* 1996;275(7):521-7.

Pope HG Jr, et al. Early-onset cannabis use and cognitive deficits: what is the nature of the association? *Drug Alcohol Depend*. 2003 Apr 1;69(3):303-10;

Radhakrishnan R, Wilkinson ST, D'Souza DC. Gone to Pot - A Review of the Association between Cannabis and Psychosis. *Front Psychiatry*. 2014 May 22;5:54.

Ramaekers JG, Robbe HW, O'Hanlon JF. Marijuana, alcohol and actual driving performance. *Hum Psychopharmacol* 2000;15(7):551-8.

Ramaekers JG, Theunissen EL, de Brouwer M, Toennes SW, Moeller MR, Kauert G. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. *Psychopharmacology (Berl)*. 2011 Mar;214(2):391-401.

Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. *Psychopharmacology (Berl)*. 2006 Nov;188(4):425-44.

Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. *Addiction*. 1998 Jun;93(6):837-46.

Robbe HW, O'Hanlon JF. Marijuana and actual driving performance. *US Department of Transportation/National Highway Traffic Safety Administration* November: 1-133 (1993). DOT HS 808 078.

Robson PJ. Therapeutic potential of cannabinoid medicines. *Drug Test Anal*. 2014 Jan-Feb;6(1-2):24-30.

Robson P. Abuse potential and psychoactive effects of δ -9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. *Expert Opin Drug Saf*. 2011 Sep;10(5):675-85.

Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA. Cannabidiol, a non-psychoactive component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. *Br J Pharmacol*. 2012 Apr;165(8):2620-34.

Rog DJ. Cannabis-based medicines in multiple sclerosis--a review of clinical studies. *Immunobiology*. 2010 Aug;215(8):658-72.

Salomonsen-Sautel S, Min SJ(2), Sakai JT, Thurstone C, Hopfer C., Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado, *Drug Alcohol Depend.* 2014 Apr 23 epub

Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. *Curr Drug Targets CNS Neurol Disord.* 2005 Dec;4(6):677-84. Review.

Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. *Hum Psychopharmacol.* 2011 Apr;26(3):224-36.

Schweinsburg AD, Schweinsburg BC, Nagel BJ, Eyster LT, Tapert SF. Neural correlates of verbal learning in adolescent alcohol and marijuana users. *Addiction.* 2011 Mar;106(3):564-73.

Seeman P. Discovery of why acute lymphoblastic leukaemia cells are killed by asparaginase: Adventures of a young post-doctoral student, Bertha K Madras. *J Med Biogr.* 2013 Sep 27;22(2):90-92.

Seeman, P and Madras BK, editors. *Imaging of the Human Brain in Health and Disease* Elsevier Press, 2014.

Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. *Diabetes Care.* 2010 Jan;33(1):128-30.

Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. *Eur J Pain.* 2014 Aug;18(7):999-1012

Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D'Souza DC. Acute effects of THC on time perception in frequent and infrequent cannabis users. *Psychopharmacology (Berl).* 2013 Mar;226(2):401-13.

Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. *Int Rev Psychiatry.* 2009 Apr;21(2):152-62. doi: 10.1080/09540260902782802. Review.

Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D'Souza DC. Acute effects of THC on time perception in frequent and infrequent cannabis users. *Psychopharmacology (Berl).* 2013 Mar;226(2):401-13

Shohami E, Novikov M, Mechoulam R. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. *J Neurotrauma.* 1993 Summer;10(2):109-19.

Skosnik PD, Ranganathan M, D'Souza DC. Cannabinoids, working memory, and schizophrenia. *Biol Psychiatry*. 2012 Apr 15;71(8):662-3.

Skosnik PD, Krishnan GP, D'Souza DC, Hetrick WP, O'Donnell BF. Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis Users. *Neuropsychopharmacology*. 2014 Jul 3. [epub]

Smiley A, Moskowitz HM, Ziedman K. Effects of drugs on driving: Driving simulator tests of secobarbital, diazepam, marijuana, and alcohol. In *Clinical and Behavioral Pharmacology Research Report*. J.M. Walsh, Ed. U.S. Department of Health and Human Services, Rockville, 1985, pp 1-21.

Smith MJ, Cobia DJ, Wang L, Alpert KI, Cronenwett WJ, Goldman MB, Mamah D, Barch DM, Breiter HC, Csernansky JG. Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. *Schizophr Bull*. 2014 Mar;40(2):287-99.

Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. *Pain Pract*. 2014 Feb;14(2):167-84

Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundhwala Y, Botteman M. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. *Int J Clin Pract*. 2014 Jul;68(7):900-18.

Söderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. *Pharmacol Biochem Behav*. 2001 Jul-Aug;69(3-4):343-50.

Solowij N, Michie PT, Fox AM. Differential impairment of selective attention due to frequency and duration of cannabis use. *Biol Psychiatry* 1995;37(10):731-9.

Solowij N, Walterfang M, Lubman DI, Whittle S, Lorenzetti V, Styner M, Velakoulis D, Pantelis C, Yücel M. Alteration to hippocampal shape in cannabis users with and without schizophrenia. *Schizophr Res*. 2013 Jan;143(1):179-84.

Solowij N, Yücel M, Respondek C, Whittle S, Lindsay E, Pantelis C, Lubman DI. Cerebellar white-matter changes in cannabis users with and without schizophrenia. *Psychol Med*. 2011 Nov;41(11):2349-59.

Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. *Curr Drug Abuse Rev*. 2008 Jan;1(1):81-98. Review.

Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. *Schizophr Res*. 2014 Jul;156(2-3):211-6.

Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA. Age at initiation of cannabis use predicts age at onset of psychosis: the 7- to 8-year trend. *Schizophr Bull*. 2013 Mar;39(2):251-4.

Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/cannabidiol (sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. *Drugs*. 2014 Apr;74(5):563-78.

Szutorisz H, DiNieri JA, Sweet E, Egervari G, Michaelides M, Carter JM, Ren Y, Miller ML, Blitzer RD, Hurd YL. Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. *Neuropsychopharmacology*. 2014 May;39(6):1315-23.

Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association? *Br J Psychiatry* 1990;157:25-33.

Taffe MA. Δ^9 Tetrahydrocannabinol impairs visuo-spatial associative learning and spatial working memory in rhesus macaques. *J Psychopharmacol*. 2012 Oct;26(10):1299-306.

TEDS Report, Feb 2 2012, Marijuana admissions reporting daily use at treatment entry.

Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. *Am J Cardiol*. 2014 Jan 1;113(1):187-90

Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. *J Natl Compr Canc Netw*. 2012 Apr;10(4):487-92.

Tortoriello G, Morris CV, Alpar A, Fuzik J, Shirran SL, Calvigioni D, Keimpema E, Botting CH, Reinecke K, Herdegen T, Courtney M, Hurd YL, Harkany T. Miswiring the brain: Δ^9 -tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. *EMBO J*. 2014 Apr 1;33(7):668-85.

Varma VK, Malhotra AK, Dang R, Das K, Nehra R. Cannabis and cognitive functions: a prospective study. *Drug Alcohol Depend* 1988;21(2):147-52.

Vindenes V, Strand DH, Kristoffersen L, Boix F, Mørland J. Has the intake of THC by cannabis users changed over the last decade? Evidence of increased exposure by analysis of blood THC concentrations in impaired drivers. *Forensic Sci Int*. 2013 Mar 10;226(1-3):197-201.

Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. *J Neurochem.* 1993 Jul;61(1):352-5.

Volkow ND, Wang GJ, Telang F, Fowler JS, Alexoff D, Logan J, Jayne M, Wong C, Tomasi D. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. *Proc Natl Acad Sci U S A.* 2014 Jul 14.

Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. *N Engl J Med.* 2014 Jun 5;370(23):2219-27.

Wadsworth EJ, Moss SC, Simpson SA, Smith AP. Cannabis use, cognitive performance and mood in a sample of workers. *J Psychopharmacol* 2006;20(1):14-23

Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ.* 2010 Oct 5;182(14):E694-701.

Wilkinson ST, D'Souza DC. Problems with the medicalization of marijuana. *JAMA.* 2014 Jun 18;311(23):2377-8. doi: 10.1001/jama.2014.6175. PubMed PMID: 24845238.

Wilkinson ST, D'Souza DC. Problems with the medicalization of marijuana. *JAMA.* 2014 Jun 18;311(23):2377-8.

Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. (2013). Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. *J Pain*, 14(2):136-48.

Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. (2008) A Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain. *J Pain*, 9(6):506-21.

Wright MJ Jr, Vandewater SA, Taffe MA. Cannabidiol attenuates deficits of visuospatial associative memory induced by $\Delta(9)$ tetrahydrocannabinol. *Br J Pharmacol.* 2013 Dec;170(7):1365-73.

Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, Lubman DI. Regional brain abnormalities associated with long-term heavy cannabis use. *Arch Gen Psychiatry.* 2008 Jun;65(6):694-701.

Yücel M, Zalesky A, Takagi MJ, Bora E, Fornito A, Ditchfield M, Egan GF, Pantelis C, Lubman DI. White-matter abnormalities in adolescents with long-term inhalant and cannabis use: a diffusion magnetic resonance imaging study. *J Psychiatry Neurosci.* 2010 Nov;35(6):409-12.

Zalesky A, Solowij N, Yücel M, Lubman DI, Takagi M, Harding IH, Lorenzetti V, Wang R, Searle K, Pantelis C, Seal M. Effect of long-term cannabis use on axonal fibre connectivity. *Brain.* 2012 Jul;135(Pt 7):2245-55.

Zeltser R, Seltzer Z, Eisen A, Feigenbaum JJ, Mechoulam R. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoids with NMDA receptor-blocking properties. *Pain*. 1991 Oct;47(1):95-103.